Tissue factor pathway inhibitor in thrombosis and beyond.
Mousa
Shaker A
SA
Albany College of Pharmacy, NY, USA.
Fareed
Jawed
J
Iqbal
Omer
O
Kaiser
Brigitte
B
D000789:Angina, Unstable / Q000209:etiology; D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology; D001161:Arteriosclerosis / Q000209:etiology; D001777:Blood Coagulation / Q000502:physiology; D004211:Disseminated Intravascular Coagulation / Q000209:etiology; D004347:Drug Interactions; D005343:Fibrinolytic Agents / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D008074:Lipoproteins / Q000494:pharmacology / Q000502:physiology*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D009203:Myocardial Infarction / Q000209:etiology; D018805:Sepsis / Q000209:etiology; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy / Q000209:etiology*
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D008074:Lipoproteins; C051928:lipoprotein-associated coagulation inhibitor; D006493:Heparin